New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
05:49 EDTPSTIPluristem CEO says muscle injury study suggests PLX-PAD effective treatment
Pluristem Therapeutics issued a Letter to Shareholders from its CEO, Zami Aberman. Aberman stated, "We have started 2014 with strong momentum on many fronts, including advancements in our clinical pipeline and regulatory approvals surrounding our cell therapy production methods and new manufacturing facility. The outstanding safety and efficacy results of our Phase I/II muscle injury study announced in January suggest that PLX-PAD cells may be effective in the treatment of muscle and tendon injuries. We analyzed the potential for a variety of orthopedic indications. Based on our findings and in keeping with our strategy, we have decided to move forward with at least two clinical indications, which will be announced in the next few weeks. Enrollment of the Phase II intermittent claudication, or IC, study is moving forward in the U.S., Germany and Israel and we expect to initiate enrollment in South Korea shortly."
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PSTI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use